CXCR2 and neoplasm: Nywening et al. have recently reported that dual blocking of CXCR2+ TANs and CCR2+ TAMs disrupted the recruitment of myeloid cells and improved anti-tumor immunity in a mouse model of pancreatic cancer [61].